# ToxAgent V2: Multi-Source Toxicity Intelligence

This document outlines the architectural expansion of the ToxAgent module to incorporate data sources beyond official labeling (SPL) and adverse event reporting (FAERS).

## 🏗️ 1. Scientific Literature Mining (PubMed/PMC)
Extracting signals from peer-reviewed clinical research and case reports.
- **Rationale:** Labeling often lags behind academic literature by 12–24 months. Early-stage signals (e.g., rare idosyncratic DILI) often appear first as published case reports.
- **Implementation:**
    - Integration with the **Entrez Programming Utilities (E-Utils)**.
    - Automated extraction of "Case Report" and "Clinical Trial" publication types.
    - NLP-based scoring of "Causality" using criteria like the Naranjo Scale or Roussel Uclaf Causality Assessment Method (RUCAM) extracted from text.

## 🧪 2. Comparative Regulatory Intelligence (Global Scat)
Monitoring safety actions from non-US regulatory bodies.
- **Rationale:** Regulatory agencies like the **EMA (Europe)**, **Health Canada**, and **PMDA (Japan)** may issue safety warnings or label updates before the FDA for specific drugs.
- **Implementation:**
    - Scrapers for EMA's "Referrals" and "Safety communications."
    - Cross-referencing global "Black Box" warnings to identify discrepancies where a drug is restricted in one region but remains unrestricted in another.

## 🧬 3. Structure-Activity Relationship (SAR) & QSAR
Predicting toxicity based on chemical structure.
- **Rationale:** Identifying "Toxicophores" (chemical sub-structures known to cause specific organ damage). Useful for assessing "New Molecular Entities" or identifying why a specific class of drugs (e.g., Statins) shares a common toxicity profile.
- **Implementation:**
    - Integration with **PubChem** or **ChEMBL** to retrieve SMILES strings.
    - Read-across analysis: "This drug is structurally 90% similar to Molecule X, which was withdrawn for cardiotoxicity."

## 🔬 4. Mechanistic Pathway Analysis (Tox21 / ToxCast)
Linking molecular targets to toxic outcomes.
- **Rationale:** Understanding the *why* behind the toxicity (e.g., inhibition of the BSEP transporter leading to cholestatic liver injury).
- **Implementation:**
    - Mapping drugs to biological pathways using **KEGG** or **Reactome**.
    - Querying high-throughput screening data from the **Tox21** program to identify molecular "stress response" triggers.

## 📡 5. Real-World Evidence (RWE) / Social Listening
Monitoring digital health data and patient forums.
- **Rationale:** Capturing "low-grade" toxicities that patients may not report to a doctor but discuss in peer groups (e.g., cognitive "brain fog" or specific muscle pains).
- **Implementation:**
    - Targeted monitoring of specialized medical subreddits or health forums using sentiment analysis.
    - Integration with anonymized EHR (Electronic Health Record) trend data (if available via internal hooks).

## 📊 6. Biomarker-Toxicity Correlation (The PGx Link)
Using genomic data to predict who will experience toxicity.
- **Rationale:** Many toxicities are HLA-mediated (e.g., Stevens-Johnson Syndrome). Correlating tox signals with the **PGx Agent**'s biomarker data creates a "Personalized Safety Profile."
- **Implementation:**
    - Automated "Risk Flagging" when a drug has both a high FAERS count for a specific PT AND a known genomic biomarker required for metabolism.

---

## 📈 Integration Roadmap
| Feature | Complexity | Impact | Data Source |
| :--- | :--- | :--- | :--- |
| Global Regulatory | Low | High | Web Scrapers |
| Literature Mining | Medium | High | PubMed API |
| SAR / Read-across | High | Medium | ChEMBL / RDKit |
| Mechanistic | High | Medium | Tox21 Database |
